Equibles does not estimate personal net worth.
Get an email with a short summary when Arcutis Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARQT alertsLatha Vairavan is recorded as CFO at Arcutis Biotherapeutics, Inc. (ARQT). The newest filing on record that lists Latha Vairavan as CFO at Arcutis Biotherapeutics, Inc. (ARQT) is dated April 21, 2026. Arcutis Biotherapeutics, Inc. reported in an 8-K filed April 10, 2025 that Latha Vairavan was appointed Chief Financial Officer (CFO). The proxy statement of Arcutis Biotherapeutics, Inc. reports total compensation of $1,924,780 for Latha Vairavan in fiscal 2025, including a base salary of $419,485. Latha Vairavan has spoken on 10 earnings calls and 3 other investor events across 1 company, most recently for Arcutis Biotherapeutics, Inc. on September 16, 2026. Arcutis Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcutis Biotherapeutics, Inc. includes Todd Franklin Watanabe (CEO and Board Member), Masaru Matsuda (General Counsel), David Topper (Chief Accounting Officer) and 7 others.
“Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession.”
“So, yeah, we did increase our guidance in the Q2 call, 525 to 540, based on a strong performance in Q2, and the investments we're making in the initiative to drive growth for the rest of the year.”
“In the second quarter, we generated net product revenues of $129.9 million, representing a 59% increase from the second quarter of 2025. This year-over-year increase was driven primarily by increased patient demand, as well as improvements in gross-to-net sales deductions.”
“No, I was going to add something similar. So, yeah, I think also some of that effect, you would have seen it prolong in March when we didn't. We saw the demand pick up.”
“We generated net product revenues in the quarter of $105.4 million, which is up 65 percent from Q1 of 2025. This year-over-year increase was driven primarily by increased patient demand.”
“So, So, and as you know, Serge, we just put out our earnings at $127.5 million of product revenues for Q4, and that was almost 85% year-over-year growth on our net sales.”
Start not stated–present
Last confirmed April 21, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | $419,485 | $1,924,780 |
